An update on endometriosis biomarkers

Kyle N LE, Camran Nezhat, Ceana Nezhat, Ariel Benor, Alan Decherney
Minerva obstetrics and gynecology · 2024 · vol. 76(5) , pp. 458–469 · doi:10.23736/S2724-606X.23.05369-1 · PMID:38602013
review OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review identifies and categorizes novel biomarkers for endometriosis, highlighting the emerging utility of microRNA for diagnosis and prognosis despite the lack of a currently validated single biomarker.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This paper is a brief 2024 free-access review that surveys and categorizes emerging endometriosis biomarkers, focusing on diagnostic and prognostic potential. It outlines the clinical background that diagnosis is currently histologic via biopsy (or empiric diagnosis based on symptom response to treatment) and notes that there is no single validated biomarker, while highlighting emerging evidence for microRNA in relation to diagnosis and disease activity. A stated limitation is that the review does not claim validation of any biomarker, reflecting the current lack of validated single tests. This paper is centrally about endometriosis — it reviews and categorizes candidate endometriosis biomarkers, especially microRNA-based diagnostics/prognostics.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a debilitating gynecologic disorder characterized by chronic pelvic pain, pelvic adhesions and infertility. The gold standard diagnostic modality is histologically by tissue biopsy, although it can be diagnosed empirically if symptoms improve with medical treatment. A delayed diagnosis of endometriosis often leads to a significant impairment in quality of life and work productivity; hence, significant morbidity has been shown to bear a detrimental impact on society and the economy. The ongoing novel investigation into biomarkers for diagnostic or prognostic evaluation of endometriosis may aid in earlier detection, and thereby, improve patient quality-of-life as well as minimize morbidity. Currently, no single biomarker has been validated for endometriosis; however, there are emerging data on the utility of microRNA for diagnosis and prognosis of disease activity. In this brief review, we will identify and categorize the novel biomarkers for endometriosis.
Full text 2,076 characters · extracted from oa-doi-fallback · click to expand
JOURNAL TOOLS | | Journal policies | | Publishing options | | eTOC | | To subscribe | | Submit an article | | Recommend to your librarian | ARTICLE TOOLS | | Publication history | | Reprints | | Permissions | | Cite this article as | | Share | YOUR ACCOUNT YOUR ORDERS SHOPPING BASKET Items: 0 Total amount: € 0,00 HOW TO ORDER YOUR SUBSCRIPTIONS YOUR ARTICLES YOUR EBOOKS COUPON ACCESSIBILITY REVIEW Free access Minerva Obstetrics and Gynecology 2024 October;76(5):458-69 DOI: 10.23736/S2724-606X.23.05369-1 Copyright © 2023 EDIZIONI MINERVA MEDICA language: English An update on endometriosis biomarkers Kyle N. LE 1 ✉, Camran NEZHAT 2, Ceana NEZHAT 3, Ariel BENOR 4, Alan DECHERNEY 4 1 Cooper University Hospital, Camden, NJ, USA; 2 Camran Nezhat Institute, Minimally Invasive & Robotic Surgery, Redwood, CA, USA; 3 Atlanta Center for Minimally Invasive Surgery & Reproductive Medicine, Atlanta, GA, USA; 4 Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA Endometriosis is a debilitating gynecologic disorder characterized by chronic pelvic pain, pelvic adhesions and infertility. The gold standard diagnostic modality is histologically by tissue biopsy, although it can be diagnosed empirically if symptoms improve with medical treatment. A delayed diagnosis of endometriosis often leads to a significant impairment in quality of life and work productivity; hence, significant morbidity has been shown to bear a detrimental impact on society and the economy. The ongoing novel investigation into biomarkers for diagnostic or prognostic evaluation of endometriosis may aid in earlier detection, and thereby, improve patient quality-of-life as well as minimize morbidity. Currently, no single biomarker has been validated for endometriosis; however, there are emerging data on the utility of microRNA for diagnosis and prognosis of disease activity. In this brief review, we will identify and categorize the novel biomarkers for endometriosis. KEY WORDS: Endometriosis; Biomarkers; Infertility

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosischronic_pelvic_paininfertility

MeSH descriptors

Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers Biomarkers

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-06-18T06:15:08.409253+00:00
pubmed
last seen: 2026-06-18T06:13:10.999781+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine